Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. - Wikidata - wikimedia - TriplyDB

Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.

Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.

http://www.wikidata.org/entity/Q34180615

about

Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence - a narrative review Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges Multipurpose prevention technologies: the future of HIV and STI protection Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study Disclosure of pharmacokinetic drug results to understand nonadherence Perceived Advantages and Disadvantages of Using Pre-Exposure Prophylaxis (PrEP) among Sexually Active Black Women: An Exploratory Study.Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery Rethinking HIV prevention to prepare for oral PrEP implementation for young African women Beyond "getting drugs into bodies": social science perspectives on pre-exposure prophylaxis for HIV.Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa.Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.The preexposure prophylaxis revolution; from clinical trials to programmatic implementation.HIV pre-exposure prophylaxis for women.Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa.Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy.Can a pill prevent HIV? Negotiating the biomedicalisation of HIV prevention.Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.Attitudes and perceptions towards novel objective measures of ARV-based vaginal ring use: Results from a global stakeholder survey.Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial.Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?Vaginal Prostate Specific Antigen (PSA) Is a Useful Biomarker of Semen Exposure Among HIV-Infected Ugandan Women.Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.Acceptability and preferences for safer conception HIV prevention strategies: a qualitative study.Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design.Women and ARV-based HIV prevention - challenges and opportunities.PrEP Implementation Science: State-of-the-Art and Research Agenda.Women and ARV-based prevention: opportunities and challenges.Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women.Motivations and barriers to uptake and use of female-initiated, biomedical HIV prevention products in sub-Saharan Africa: an adapted meta-ethnography.Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study.Optimizing adherence in HIV prevention product trials: Development and psychometric evaluation of simple tools for screening and adherence counseling.Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1 serodiscordant couples in East Africa: a qualitative evaluation study in Uganda.Stakeholder engagement to inform HIV clinical trials: a systematic review of the evidence

P2860

Q26778293-BA61FCD2-643B-48AB-AB82-1D421EDF676C Q26825641-FF5141C4-0C47-41CE-AC23-6D576382FBBA Q26827796-30DB1B3B-CA5C-4521-8B93-8409087C38F9 Q27300707-69ADB2E8-DAD0-4EE0-A369-33838D16D5AE Q30674432-02F327EE-DA78-4700-AD26-1BB19B394390 Q33908319-769083E6-5029-470D-94C8-D7E6E7540BB3 Q35541521-64EF768D-839E-4B40-B2EE-DCACFDAA416D Q35875710-13354627-3426-4231-879C-624D6A017EC4 Q35875729-D0ABB49A-C909-4554-85F5-538F3B01F4A8 Q36144731-6AFAEE97-60CB-4A7A-9652-556A91346297 Q36443803-DAB70FB2-BB60-4155-8D6C-326AB4B5DA9D Q36988613-1B27CB59-5BD1-41D0-AE6F-EA5D75A93B51 Q37141403-83DE8F31-35F0-40EE-838A-602C8456200D Q37348460-199DB579-E888-4708-BDB9-9ACB7FDF4091 Q37352568-95B3BFFD-FC27-4BB8-AD1B-01919B5602C3 Q37404649-77524EE2-3732-4E2B-8189-ACB7A4A94B89 Q37736062-F4D5055C-0031-4BE7-8630-60724AEFDC38 Q38678847-ACFC9EF8-8493-401E-94DC-42B2FCA3A911 Q38849514-CFE8ED4A-CF9A-4A4E-A363-D0851171EC0C Q38852654-5C61F6FB-81FE-479C-BEFA-8B33C8F036E9 Q38854447-590C7F7F-95F9-4E51-849C-9173E31B50D9 Q40062702-15DC6807-13AF-4673-90E6-E707E1C5DE77 Q40281007-83755C45-D24A-4C64-ACB4-F6E5879CEB64 Q40992145-C8885AED-2818-48AC-95AC-660548381784 Q42668432-B3FDD4EF-6E5E-42EF-9410-8725C44E6C97 Q42877276-EA4B64BF-3B29-4E2D-9052-F49B9F063791 Q43241737-5DCAE26F-5F2E-42C7-A1D0-DB03DBA864BE Q46553256-32892378-4DBD-47E3-8685-7FC1E8981751 Q47105640-81413400-DF7B-4E30-AB0F-86912FCDF8F3 Q47107885-64E98947-D207-4060-B3A3-4B4F639A9D15 Q50114646-4BF3C495-191B-44DA-B508-A1E3AAB37DF9 Q52323543-82865EB5-EA72-4230-9E17-907113859B1D Q53837345-CDD9A171-24FA-4605-AD35-90D04736C6CD Q54961974-6B5D2D59-C85E-492C-8C0F-390ADF45B285 Q58595713-E6FDF70F-B87A-41E5-B306-BF607E99D9D4

P2860

Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.

http://www.wikidata.org/entity/Q34180615

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Perspectives on use of oral an ...... in Johannesburg, South Africa.

@ast

Perspectives on use of oral an ...... in Johannesburg, South Africa.

@en

Perspectives on use of oral an ...... in Johannesburg, South Africa.

@nl

type

label

Perspectives on use of oral an ...... in Johannesburg, South Africa.

@ast

Perspectives on use of oral an ...... in Johannesburg, South Africa.

@en

Perspectives on use of oral an ...... in Johannesburg, South Africa.

@nl

prefLabel

Perspectives on use of oral an ...... in Johannesburg, South Africa.

@ast

Perspectives on use of oral an ...... in Johannesburg, South Africa.

@en

Perspectives on use of oral an ...... in Johannesburg, South Africa.

@nl

P1433

Q34180615-775A0F30-D1C9-4285-8FDB-3D3FFCB226CB

P1476

Q34180615-B9F3C547-2225-4CAA-896D-9BCBD6FCFA87

P2093

Q34180615-18943A54-8EC1-4278-BB6E-E946EB09BD61

Q34180615-73EAB030-B9B8-47DA-A46B-1DBEA1314178

Q34180615-7C640BA3-6C5F-46D2-B4A0-573995CE5B21

Q34180615-B2C93AC7-CE1D-43DA-8F3B-AFC7796788B6

Q34180615-E0DF757B-D4ED-4893-98D2-8762121B09C5

Q34180615-E6C67BE6-1491-44D6-A7E1-11CEAD30B97C

P2860

Q34180615-01CAAEA3-CF48-4B9C-A8FE-93DDF0C22A4B

Q34180615-01FEC119-B898-42C3-A4C7-E3F96EC820C1

Q34180615-09ACD7A0-7EFA-4DB1-A668-5EB2A543CB6F

Q34180615-0B720215-DB29-49C2-BE59-0C92AE44A6C2

Q34180615-191CE945-8AC5-4041-A7FC-715CFFE1FAF1

Q34180615-1CBC517E-DA40-4CB3-A410-C418EF478A44

Q34180615-1DBE2D65-9246-4339-8F21-5F063F7B37CF

Q34180615-2AE1F2A9-EE8B-4E66-A5B8-7139C57C66A4

Q34180615-306FBDF6-6D8F-48B8-BFB7-E281A221E1F6

Q34180615-3716A99C-D688-4EC9-AEDF-6F6A95F17FF3

P304

Q34180615-61DEB953-2109-4B28-85BF-26A7281E629A

P31

Q34180615-4D2C9499-F3EC-49DF-B1E6-12F02BB25065

P356

Q34180615-59BC4E6F-6D08-48A4-87DF-92CDB37FCD19

P433

Q34180615-73FF5E21-4092-4836-91A4-2144A821AE25

P478

Q34180615-7684FBC0-C93F-4747-91E8-DB29B41DDFB4

P50

Q34180615-3291328D-62BD-40B5-823C-F646D294DC0D

P577

Q34180615-B977167D-CA91-4347-BE82-DF8D9A16E65A

P698

Q34180615-5814F9BA-CA25-433F-ABAE-2EB01DC767ED

P921

Q34180615-0BA4EF57-E22D-49CC-A98B-49FE619E174E

Q34180615-3769BCFD-AC93-4CD2-B493-49871107BB7F

Q34180615-41541A6F-7C45-4CF0-9715-AE786142F1BC

Q34180615-81BF651D-F0D7-4F44-9303-2FE7F7B16CF7

Q34180615-F07FE389-51EC-4C43-A6BB-D6653D8DA652

P932

Q34180615-D76AECF2-1CF1-41A9-9444-9746F9B098ED

P356

P1433

Journal of the International AIDS Society

P1476

Perspectives on use of oral an ...... in Johannesburg, South Africa.

@en

P2093

Ariane van der Straten

http://www.w3.org/2001/XMLSchema#string

Elizabeth T Montgomery

http://www.w3.org/2001/XMLSchema#string

Ellen Luecke

http://www.w3.org/2001/XMLSchema#string

Miriam Hartmann

http://www.w3.org/2001/XMLSchema#string

Nicole Laborde

http://www.w3.org/2001/XMLSchema#string

VOICE-C Study Team

http://www.w3.org/2001/XMLSchema#string

P2860

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial

Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa

Preexposure prophylaxis for HIV infection among African women

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

State of the science of adherence in pre-exposure prophylaxis and microbicide trials.

Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: a social ecological approach.

Denial and defiance: a socio-political analysis of AIDS in South Africa.

P304

19146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7448/IAS.17.3.19146

http://www.w3.org/2001/XMLSchema#string

P433

3 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan Stadler

P577

2014-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25224610

http://www.w3.org/2001/XMLSchema#string

P921

Aafrikaa Kibbaa

antiretroviral drug

prevention of HIV/AIDS

P932

4163995

http://www.w3.org/2001/XMLSchema#string